Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimportation Bill From Dorgan/Snowe Includes User Fees To Fund Oversight

Executive Summary

A reimportation bill reintroduced by Sens. Byron Dorgan (D-N.D.) and Olympia Snowe (R-Maine) includes user fees for importers and foreign exporters to fund FDA's safety oversight

You may also be interested in...



Drug Importation Often Driven By Personal, Not Pricing, Concerns, FDA Finds

Prescription-free access to pharmaceuticals, as opposed to saving money, is the motivation for a large number of Americans who purchase drugs online, according to FDA Acting Deputy Commissioner-Policy Randall Lutter

Drug Importation Often Driven By Personal, Not Pricing, Concerns, FDA Finds

Prescription-free access to pharmaceuticals, as opposed to saving money, is the motivation for a large number of Americans who purchase drugs online, according to FDA Acting Deputy Commissioner-Policy Randall Lutter

Rx Importation Legislation Debate Begins Anew, But Battle Lines Are Familiar

Sens. Byron Dorgan, D-S.D., and Olympia Snowe, R-Maine, are trying to build momentum for their proposal to allow prescription drug importation, vowing at a March 7 hearing that they will push to bring the measure quickly to the Senate floor

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel